CD8A and neoplasm: Our findings are consistent with the critical role of endogenous NK cells and CD8+ T cells in anti-tumor immunity, and support that autologous NK cell therapy is effective in treating established low burden MHC-I+ metastases by enhancing the tumor-specific CD8+ T cell response.